Faeth Therapeutics (FTH) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.79
- Estimate
- -$0.71
- Surprise
- -10.5%
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Faeth Therapeutics (FTH) reported a wider loss than forecast — adjusted EPS of -$0.79 against the -$0.71 estimate (a 10.5% shortfall).
Coverage in the report window
- Faeth Therapeutics Q3 EPS $(0.79) Misses $(0.71) Estimate — benzinga, 2026-11-03
Where TrendMatrix's rating stands now
TrendMatrix currently rates FTH Sell at 5.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -10.5% surprise compares with a -5262.4% four-quarter average.
What argues against it
- Concentration risk — Pipeline: PIKTOR
- Quality below floor (2.0 < 4.0)
- Momentum score 3.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.65
- Price target
- $48.18
- Stop
- $18.27
- Upside to target
- +145.2%
- Reward-to-risk
- 9.7:1
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
FTH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $507.8M
- P/E (fwd)
- -5.4
- 52-week range
- $7.45–$42.14
- Off 52-week high
- 53.4%
- RSI (14)
- 49
- Volume vs avg
- 0.55×
- Score today
- 5.3/10